Percheron Therapeutics Ltd
ASX:PER

Watchlist Manager
Percheron Therapeutics Ltd Logo
Percheron Therapeutics Ltd
ASX:PER
Watchlist
Price: 0.068 AUD -8.11% Market Closed
Market Cap: 70.5m AUD
Have any thoughts about
Percheron Therapeutics Ltd?
Write Note

Percheron Therapeutics Ltd
Effect of Foreign Exchange Rates

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Percheron Therapeutics Ltd
Effect of Foreign Exchange Rates Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Effect of Foreign Exchange Rates CAGR 3Y CAGR 5Y CAGR 10Y
Percheron Therapeutics Ltd
ASX:PER
Effect of Foreign Exchange Rates
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mayne Pharma Group Ltd
ASX:MYX
Effect of Foreign Exchange Rates
-AU$847k
CAGR 3-Years
54%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Neuren Pharmaceuticals Ltd
ASX:NEU
Effect of Foreign Exchange Rates
AU$3.8m
CAGR 3-Years
N/A
CAGR 5-Years
41%
CAGR 10-Years
N/A
Botanix Pharmaceuticals Ltd
ASX:BOT
Effect of Foreign Exchange Rates
AU$86.2k
CAGR 3-Years
96%
CAGR 5-Years
27%
CAGR 10-Years
N/A
Probiotec Ltd
ASX:PBP
Effect of Foreign Exchange Rates
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Arovella Therapeutics Ltd
ASX:ALA
Effect of Foreign Exchange Rates
AU$23k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Percheron Therapeutics Ltd
Glance View

Market Cap
70.5m AUD
Industry
Pharmaceuticals

Percheron Therapeutics Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-12-20. Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a biotechnology company. The firm is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Company’s products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The firm is conducting a Phase II clinical trial of ATL1102 in DMD patients.

PER Intrinsic Value
0.066 AUD
Overvaluation 2%
Intrinsic Value
Price

See Also

Back to Top